Biotech Values

[10nisman]

If MNTA is serious about spending a non-trivial amount of its own money to take M118 through phase-2b/phase-3, MNTA ought to consider a transaction to monetize its future cash flows from Lovenox, similar to what VRTX did with JNJ/ Mitsubishi on the ex-US milestone payments for Telaprevir. I think NVS would pay well north of $1B up-front for MNTA’s cash flows from Lovenox.

Dew, have you spoken to CW or RS about potentially doing a transaction to monetize mLovenox cash flows? Just curious to know their potential interest or if its even something on their radar.

10nis